The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit

Withdrawn before enrolling · Phase 3

Conditions studied: Constipation, Critical Illness

In brief

Naloxegol has recently been approved by the US Food and Drug Administration to treat opioid induced constipation in non-cancer chronic pain patients. Its effectiveness in acute care patients, however, is not known. Therefore, the researchers' goal is to investigate whether naloxegol is superior to osmotic laxatives for refractory constipation in ICU patients already receiving prophylactic stool softeners and simulant laxatives through a double-blind, randomized control trial.

Key facts

Study ID

NCT02705378

Run by

Massachusetts General Hospital

People needed

0

Starts

2017-05-01

Expected to finish

2019-12-01

Last updated by the study team

2021-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• Admitted to an ICU at Massachusetts General Hospital (MGH)
• Received ≥72 hours of continuous opioid infusion
• Anticipated to require ≥48 hours of additional care in the ICU
• Did not have a bowel movement in ≥72 hours
• Allowed to receive (and tolerating) medications via nasogastric, orogastric, gastric, gastrojejunal, or oral route
• Receiving at least trophic (10 mL/hr) of enteral nutrition

You may not qualify if…

• Unable to provide informed consent or unavailable healthcare proxy
• Not expected to survive >48 hours from time of enrollment
• "Comfort measures only" status (i.e. palliative care)
• Received medication other that docusate and senna glycoside for laxation
• Had abdominal surgery that is expected to cause significant ileus
• Mechanical bowel obstruction
• Total bowel rest/exclusively receiving total parenteral nutrition
• History of chronic constipation unrelated to opioid use
• Compromised blood-brain-barrier
• Current diagnosis of solid organ or hematologic cancer
• On moderate/strong CYP3A4 inhibitors or strong CYP3A4 inducers
• On other opioid antagonists
• Pregnant or lactating females

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.